Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of FOLFIRI + bevacizumab with or without bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer
2009-017996-11Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoints: Disease control duration and Disease control rate at 12 months. Started Feb 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2009-017996-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017996-11.